We start pre-market with a clear liquidity signal: 44,300,000.00 shares have traded and OncoTherapy Science, Inc. (4564.T stock) sits at JPY 21.00. Volume is 1.18 times the 50-day average and puts 4564.T stock among Japan’s most active names in early trade. Traders are watching clinical catalysts and recent technical support near JPY 20.00. This update ties the intraday flow to fundamentals, giving context for short-term trading and longer-term valuation.

4564.T stock: pre-market price and volume snapshot

4564.T stock opened at JPY 22.00 and is quoted at JPY 21.00 in pre-market. The day range is JPY 20.00–22.00 and year range is JPY 19.00–35.00. Volume stands at 44,300,000.00 versus an average of 43,128,321.00, so relative volume is 1.18. This strength in liquidity makes 4564.T stock one of the most active JPX names in the session.

4564.T stock fundamentals and valuation metrics

OncoTherapy’s balance sheet shows cash per share JPY 6.06 and book value per share JPY 5.93, while shares outstanding are 343,643,599.00. Key ratios: P/B 3.54, P/S 9.20, EPS -2.83, and reported PE -7.42. Market capitalization is JPY 7,216,515,579.00. High current ratio 8.51 signals liquidity but negative profitability and high R&D intensity (R&D/revenue 65.79%) keep traditional valuation stretched.

4564.T stock: clinical pipeline and near-term catalysts

OncoTherapy’s pipeline includes peptide vaccines (S-588410 in Phase III for esophageal cancer) and small molecules (OTS167, OTS964) in early oncology trials. Phase III milestones for S-588410 represent the primary catalyst that could re-rate 4564.T stock. Company website and filings detail trial timelines and endpoints source. Positive Phase III news would materially change both sentiment and valuation.

4564.T stock technicals and trading signals

Technical indicators show mixed short-term bias: RSI 53.11 and MACD histogram 0.09 indicate neutral momentum. Bollinger band middle is JPY 20.45 with upper JPY 21.44 and lower JPY 19.46, placing current price near the middle band. MFI at 88.55 flags overbought intraday flows. For traders, support sits at JPY 20.00 and immediate resistance at JPY 22.00. Average price (50-day) is JPY 20.90 and 200-day is JPY 23.98.

4564.T stock: Meyka AI grade and model forecast

Meyka AI rates 4564.T with a score out of 100: 69.38, Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly JPY 16.61, quarterly JPY 15.60, and yearly JPY 17.31. Compared with the current price JPY 21.00, the one-year model implies -17.56% downside. Forecasts are model-based projections and not guarantees.

4564.T stock: risks and trading strategy

Principal risks are trial failure, dilution from past share issuance (weighted average shares growth 22.73%), and weak profitability metrics (ROE -63.03%). Balance-sheet strength and R&D pipeline are positives. Traders should size positions for volatility; longer-term investors should link exposure to clinical milestone timelines. For active traders, set stop-loss near JPY 19.00 and consider scaling into strength only after confirmatory trial news.

Final Thoughts

4564.T stock is highly active pre-market with 44,300,000.00 shares and a current quote of JPY 21.00. Liquidity and pipeline attention make it a short-term trading magnet on JPX, but fundamentals show negative earnings (EPS -2.83) and stretched valuation (P/S 9.20, P/B 3.54). Meyka AI’s forecast model projects a one-year target of JPY 17.31, implying -17.56% versus today’s price; scenario ranges include a bear outcome near JPY 12.52 (3-year model) and a base case around JPY 17.31. These figures are model outputs, not guarantees. Use tight risk controls, tie position sizes to catalyst timing, and track trial readouts and cash runway. For a live view, see our coverage on the Meyka AI platform Meyka stock page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.